U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

and	and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.							
Licensee 1. St. Mary Medical Center - Hobart			In accordance with letter dated April 19, 2018.	4. Expiration Date: January 31, 2026				
2.	1500 S Lake Park Ave. Hobart, IN 46342		License number: 13-03459-03 is amended in its entirety to read as follows:	5. Docket No.: 030-31379 Reference No.:				
6.	Byproduct, source, and/or special nuclear material	7. Chemical and/or physical f	form 8. Maximum amount that licen may possess at any one time under this license					
A.	Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.				
B.	Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	 For use in imaging and localization studies permitted by 10 CFR 35.200. 				
C.	Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries total	C. For any use permitted by 10 CFR 35.300.				
D.	Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 3 millicuries total	D. For use in in-vitro studies.				

NRC	FORM 374A	U.S. NUCLEAR REGULATORY COMM	SSION F	PAGE 2 OF 5 PAGES				
MATERIALS LICENSE		License Number 13-03459-03	Docket or Reference Number 030-31379					
	SUPPLEMENTARY SHEET	Amendment No. 34						
6.	Byproduct, source, 7. Chemical and and/or special nuclear material	ount that licensee 9. Authorized use at any one time nse	· · · · · · · · · · · · · · · · · · ·					
E.	Yttrium-90 permitted by E. Microsphere SIR-Spheres	s (Sirtex, Moder E. 189 millicurio	es per vial; 2 E. For use in perma	anent manual ising Sirtex Model rium-90 microspheres				
				as permitted by 10				
	to the second se	CONDITIONS	C	-				
10.	A. Licensed material listed in Subitem Ave., Hobart, Indiana.	os. 6.A. through 6 E. may be used or st	ored at the licensee's facilities located	d at 1500 S Lake Park				
	B. Licensed material listed in Subitem Ave., Hobart, Indiana.	os. 6.A. through 6.D. may also be used	or stored at the licensee's facilities lo	ocated at 300 W 61st				
	C. Licensed material listed in Subitem Nos. 6.A. through 6.B may also be used or stored at the licensee's facilities located at 3545 Arbors							
	Blvd., Portage, Indiana. D. Licensed material listed in Subitem Nos. 6 A, through 6.B may also be used or stored at the licensee's facilities located at 3800 St. Mary							
	Drive, Valparaiso, Indiana.	n M	M					
11.	The Radiation Safety Officer (RSO) for th	is license is Santosh K. Kar, M.S.						
12.	Licensed material shall only be used by,	or under the supervision of:						
	A. Individuals permitted to work as author	orized users in accordance with 10 CFR	35.13 and 10 CFR 35.14.					

FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 3 OF 5 PAGES	
MATERIALS LICENSE	License Number 13-03459-03	Docket or Reference Number 030-31379	i e	
SUPPLEMENTARY SHEET	Amendment No. 34			
B. The following individuals are author	orized users for the material and m	nedical uses as indicated:		
Authorized User(M.D.,D.O.,etc.)	Material and Use			
Samer Ajam, M.D.	10 CFR 35.200 R	311,		
Keith Atassi, M.D.	10 QFR 35.200	3ULAX		
Cam Long Choji, D.O.	10 CFR 35.200			
John W. Gustaitis, Jr., M.D.	CFR 35.100,10 CFR 35.	200,10 CFR 35,300		
Thomas M. Hoess, M.D.	10 CFR 31.11,10 CFR 35.1	00,10 CFR 35.200		
Mikhail Jeha, M.D.	10 CFR 35 100,10 CFR 35.	200		
Abdul Kawamleh, M.D.	10 CFR 35.100,10 CFR 35.	200	•	
Shawn R. Kenney, M.D.	10 CFR 31.11,10 CFR 35.1	00,10 CFR 35.200		
A. Arif Khalil, M.D.	10 CFR 35:200			
Akram Knoloki, M.D.	10 CFR 35.100,10 CFR 35.	200		
Sorin Lazar, M.D.	C 10 CFR 35,200	5		
Jonathon T. Lee, M.D.	10 CFR 31.11,10 CFR 35.1	00,10 CFR 35.200		
Mary Nicholson, M.D.	10 CFR 35.100,10 CFR 35.	200		
Charles-Lauwanga Okoro, D.O.	10 CFR 35.200	N		
Jeffery Jon Quackenbush, M.D.	10 CFR 35,300	L 43		
Anas Hakam Safadi, M.D.	10 CFR 35.200	2		
Koppolu P. Sarma, M.D.	10 CFR 35.300 (limited to the of bone pain)	ne parenteral administration of strontiur	n-89 for palliative treatme	
Harish Shah, M.D.	10 CFR 35.100,10 CFR 35.	200		
Vijah P. Shah, M.D.	10 CFR 35.100,10 CFR 35.	200		
Thomas Shin, M.D.	10 CFR 35.100,10 CFR 35.	200		
Justin Spackey, M.D.	10 CFR 35.100,10 CFR 35.	200		
Hussam Suradi, M.D.	10 CFR 35.100,10 CFR 35.	200	•	

D. Letter dated May 22, 2017 (ML17146B324)E. Letter dated June 20, 2017 (ML17172A121)

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number 13-03459-03

Docket or Reference Number 030-31379

PAGE 5 OF 5 PAGES

Amendment No. 34

- F. Letter dated September 28, 2017 (ML17276B167)

F. Letter dated September 19, 2017 (ML17354A646)

H. Letter dated December 19, 2017 (ML17353A894)

REG

2018 (ML18057A559)

JUL 0 9 2018 Date:

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Cassandra F. Frazier

Region 3